What is Attralus?
Attralus operates at the intersection of advanced biotechnology and therapeutic development, specifically targeting the underlying mechanisms of systemic amyloidosis. By leveraging a proprietary platform, the company aims to transform the standard of care for patients suffering from these debilitating conditions. As a key player in the biopharmaceutical sector, Attralus maintains a robust research and development focus, positioning itself as a critical entity in the pursuit of novel, life-altering treatments. The company's market position is defined by its commitment to scientific rigor and its ability to attract high-caliber institutional backing, which is essential for navigating the capital-intensive nature of drug discovery and clinical trials.
How much funding has Attralus raised?
Attralus has raised a total of $141M across 2 funding rounds:
Series A
$25M
Series B
$116M
Series A (2020): $25M with participation from venBio Partners
Series B (2021): $116M led by Logos Capital, Samsara BioCapital, Janus Henderson Investors, and Redmile Group
Key Investors in Attralus
Logos Capital
Logos Capital is a specialized investment firm that focuses on the healthcare and biotechnology sectors, providing strategic capital to companies developing transformative medical solutions.
Samsara BioCapital
Samsara BioCapital is focused on investing to create transformative therapeutics for patients, partnering with scientists and drug developers to support the next generation of breakthroughs.
Janus Henderson Investors
Janus Henderson is a global investment management firm that provides a broad range of investment solutions and advisory services to institutional investors and financial professionals.
What's next for Attralus?
With the successful closure of its latest funding round, Attralus is well-positioned to accelerate its clinical development programs and expand its operational capabilities. The strategic deployment of these funds will likely prioritize the advancement of its lead therapeutic candidates through critical regulatory milestones. Furthermore, the company is expected to strengthen its internal research infrastructure, ensuring that its pipeline remains competitive within the rapidly evolving landscape of rare disease therapeutics. As Attralus transitions into its next phase of growth, the focus will remain on achieving clinical validation and establishing long-term value for stakeholders, while maintaining its mission to address significant unmet medical needs in the amyloidosis space.
See full Attralus company page
